## Ariane C Gomes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4298672/publications.pdf

Version: 2024-02-01

840119 1058022 14 529 11 14 citations h-index g-index papers 14 14 14 938 docs citations times ranked citing authors all docs

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines, 2017, 5, 6.  | 2.1 | 113       |
| 2  | Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 2018, 6, 37.  | 2.1 | 113       |
| 3  | Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. Journal of Controlled Release, 2017, 251, 92-100.                                   | 4.8 | 69        |
| 4  | Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. Frontiers in Immunology, 2017, 8, 226.                     | 2.2 | 40        |
| 5  | Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015.  | 2.2 | 39        |
| 6  | Type of RNA Packed in VLPs Impacts IgG Class Switchingâ€"Implications for an Influenza Vaccine Design. Vaccines, 2019, 7, 47.  | 2.1 | 38        |
| 7  | Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines, 2017, 5, 10.    | 2.1 | 28        |
| 8  | Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS ONE, 2017, 12, e0181844.   | 1.1 | 27        |
| 9  | Microcrystalline Tyrosine (MCT $\hat{A}^{\circ}$ ): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines, 2017, 5, 32.   | 2.1 | 15        |
| 10 | The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. Vaccines, 2019, 7, 67.  | 2.1 | 12        |
| 11 | Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation. EBioMedicine, 2019, 50, 45-54.                       | 2.7 | 12        |
| 12 | Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligandsâ€"A Role for CCL2. Frontiers in Immunology, 2019, 10, 1679. | 2.2 | 10        |
| 13 | NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development. Vaccines, 2020, 8, 394.   | 2.1 | 8         |
| 14 | IgA binds to the ADâ€⊋ epitope of glycoprotein B and neutralizes human cytomegalovirus. Immunology, 2021, 162, 314-327.  | 2.0 | 5         |